Attovia Therapeutics Inc ATTO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $17.79
- Day Range
- $17.00–18.50
- 52-Week Range
- $16.15–28.00
- Bid/Ask
- $17.02 / $17.25
- Shares Outstanding
- 45.65M
- Market Cap
- $783.83M
- Volume/Avg
- 348,657 / 455,484
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 242.50
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.attovia.com
Valuation
|
Metric
|
ATTO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 242.50 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATTO
|
|---|---|
Quick Ratio | 9.13 |
Current Ratio | 9.39 |
Interest Coverage | — |
Quick Ratio
ATTO
Profitability
|
Metric
|
ATTO
|
|---|---|
Return on Assets (Normalized) | −46.08% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ATTO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$NHwH? | LOCK|>SYkH | $128B | |||
| Moderna Inc
MRNA
| LOCK|TkZrJll | LOCK|pn& | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|pLwb@V | LOCK|hwY% | $76B | |||
| argenx SE ADR
ARGX
| LOCK|GB$hY#k | LOCK|?x | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Q>BL#% | LOCK|>> | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^F?Z@# | LOCK|QxHc | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|QP$@LGK | LOCK|xTSs | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|QXmb@G& | LOCK|S% | $24B | |||
| Incyte Corp
INCY
| LOCK|>l$BpNK | LOCK|wb# | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|RH@#Bb# | LOCK|#< | $15B |
United States